Actinium Pharmaceuticals/$ATNM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Ticker
$ATNM
Sector
Primary listing
AMEX
Employees
25
Headquarters
Website
ATNM Metrics
BasicAdvanced
$47M
-
-$1.11
-0.36
-
Price and volume
Market cap
$47M
Beta
-0.36
52-week high
$2.41
52-week low
$1.03
Average daily volume
201K
Financial strength
Current ratio
7.955
Quick ratio
7.813
Long term debt to equity
3.867
Total debt to equity
8.292
Profitability
EBITDA (TTM)
-37.123
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-38,443.33%
Operating margin (TTM)
-41,486.67%
Management effectiveness
Return on assets (TTM)
-33.76%
Return on equity (TTM)
-133.09%
Valuation
Price to revenue (TTM)
523.578
Price to book
3.42
Price to tangible book (TTM)
3.42
Price to free cash flow (TTM)
-1.881
Free cash flow yield (TTM)
-53.16%
Free cash flow per share (TTM)
-0.803
Growth
Revenue change (TTM)
11.11%
Earnings per share change (TTM)
-21.05%
3-year revenue growth (CAGR)
-55.95%
3-year earnings per share growth (CAGR)
-5.26%
10-year earnings per share growth (CAGR)
-23.86%
What the Analysts think about ATNM
Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.
ATNM Financial Performance
Revenues and expenses
ATNM Earnings Performance
Company profitability
ATNM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals (ATNM) has a market cap of $47M as of December 13, 2025.
What is the P/E ratio for Actinium Pharmaceuticals stock?
The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of December 13, 2025.
Does Actinium Pharmaceuticals stock pay dividends?
No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of December 13, 2025.
When is the next Actinium Pharmaceuticals dividend payment date?
Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Actinium Pharmaceuticals?
Actinium Pharmaceuticals (ATNM) has a beta rating of -0.36. This means that it has an inverse relation to market volatility.